Mirati 007

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Trial overview

Topic

Mirati 007

Description

To evaluate the clinical activity of MRTX849 in combination with pembrolizumab administered in the first-line treatment setting to patients having NSCLC with KRAS G12C mutation.

Physicians

Contact

Florida East Coast-Jacksonville

Maddie Hamilton